Fox Run Management, L.L.C. Denali Therapeutics Inc. Transaction History

Fox Run Management, L.L.C.

  • $433 Million
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$14.96 - $23.22 $364,874 - $566,335
24,390 New
24,390 $566,000
Q2 2023

Aug 11, 2023
BUY
$23.37 - $32.96 $83,220 - $117,370
3,561 Added 39.93%
12,478 $368,000
Q1 2023

May 12, 2023
BUY
$21.91 - $32.67 $195,371 - $291,318
8,917 New
8,917 $205,000
Q3 2022

Nov 07, 2022
BUY
$25.97 - $38.53 $388,952 - $577,063
14,977 New
14,977 $460,000

Others Institutions Holding DNLI

# of Institutions
227
Shares Held
119M
Call Options Held
60.6K
Put Options Held
48.4K
View Full List

About Denali Therapeutics Inc.

DNLI Quotes by TradingView
  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.88B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Fox Run Management, L.L.C. Portfolio

Follow Fox Run Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Fox Run Management, L.L.C. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email